Brief: Precision Bio Receives Initial $7.5 Mln Cash Payment And Equity Investment From TG Therapeutics For Azel-Cel
12/02/2024 12:11
Feb 12 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES RECEIVES INITIAL $7.5 MILLION CASH
PAYMENT
AND EQUITY INVESTMENT FROM TG THERAPEUTICS FOR AZEL-CEL IN
TREATMENT OF AUTOIMMUNE DISEASES
* PRECISION BIOSCIENCES INC - EXTEND PRECISION'S CASH RUNWAY
INTO
FIRST HALF OF 2026, THROUGH PHASE 1 CLINICAL READOUTS FOR ITS
WHOLLY OWNED PROGRAMS
Source text for Eikon: ID:nBwvwftxa
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing